Introduction: Antiplatelet therapy represents a key strategy for the prevention of thrombotic
complications in patients with both acute and chronic coronary syndromes, particularly those …

For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a
platelet P2Y12 receptor inhibitor, has been the gold standard of antithrombotic …

Importance Although P2Y12 inhibitor monotherapy after a minimum period of dual
antiplatelet therapy (DAPT) is a well-known way to reduce the risk of bleeding after …

In patients with acute and chronic coronary artery disease undergoing percutaneous
coronary intervention (PCI), dual antiplatelet therapy (DAPT) has been the cornerstone of …

Platelets play a key role in mediating stent thrombosis, the major cause of ischemic events in
the immediate period following percutaneous coronary intervention (PCI). For this reason …

P2Y12 inhibitor monotherapy is a feasible alternative treatment for patients after
percutaneous coronary intervention (PCI) in the modern era. Clinical trials have shown that it …

Introduction P2Y12-inhibitor monotherapy following 1–3 months of dual antiplatelet therapy
(DAPT) reduces (major) bleeding without an apparent increase in ischemic events and has …

Abstract Background Monotherapy with P2Y12 inhibitors (P2Y12i) is emerging as alternative
strategy to dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) …

Objective To compare P2Y12 inhibitor monotherapy after 3-month dual antiplatelet therapy
(DAPT) with 12-month DAPT according to the type of P2Y12 inhibitor in patients undergoing …

Antiplatelet therapy is considered essential for secondary prevention of ischemic heart
disease. After percutaneous coronary intervention (PCI), temporary dual antiplatelet therapy …